Papp L A, Coplan J D, Martinez J M, de Jesus M, Gorman J M
Department of Clinical Psychobiology, New York State Psychiatric Institute, New York 10032,USA.
J Clin Psychopharmacol. 2000 Oct;20(5):544-6. doi: 10.1097/00004714-200010000-00009.
Fifteen patients with panic disorder participated in a 12-week treatment trial with open-label nefazodone. Nefazodone was well-tolerated with minimal side effects; none of the patients reported sexual dysfunction, and only one patient experienced weight gain. Although the response rate was lower than that found with most other antipanic medications, given its favorable side effect profile, nefazodone may be a good alternative for patients apprehensive about potential adverse drug reactions.
15名惊恐障碍患者参与了一项为期12周的开放标签奈法唑酮治疗试验。奈法唑酮耐受性良好，副作用极小；没有患者报告性功能障碍，只有1名患者体重增加。尽管缓解率低于大多数其他抗惊恐药物，但鉴于其良好的副作用特征，奈法唑酮对于担心潜在药物不良反应的患者可能是一个不错的选择。
